Skip to main content
OpenTrials
Completed

NCT Number: NCT00872339

Assessment of Pain in People With Thalassemia

Thalassemia is an inherited blood disorder that can result in mild to severe anemia. People with thalassemia often experience pain, but the exact sources and prevalence of pain remain unknown. This study will examine the prevalence and severity of pain in people with thalassemia who are treated with regular blood transfusions and people with thalassemia who are not treated with regular blood transfusions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Toronto General Hospital, Toronto, Ontario, Canada

Loading trial locations.

About this study

Thalassemia is an inherited blood disorder in which the body makes an abnormal form of hemoglobin-the protein in red blood cells that carries oxygen. People with thalassemia often experience fatigue, shortness of breath, and pain. Recent medical advances in treating people with thalassemia who receive regular blood transfusions-a standard procedure that refreshes the healthy red blood supply-have resulted in increased life spans for these people. However, with the extended life spans have come additional issues, including pain. There have been no previous research studies that have examined pain levels in people with thalassemia, and as a result, the sources and prevalence of pain remain unknown. The purpose of this study is to assess the prevalence and severity of pain, common pain sites, and the impact of pain on functioning and well-being in people with thalassemia who receive regular blood transfusions and people with thalassemia who do not receive regular blood transfusions.

This study will enroll people with transfusion-dependant thalassemia and people with non-transfusion-dependant thalassemia. At a baseline study visit, participants will complete a demographic questionnaire and a pain assessment questionnaire. At Months 3, 6, and 9, study researchers will telephone participants to go over the same pain assessment questionnaire again.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Thalassemia, as documented by clinical diagnosis, including the following:
  • B-thalassemia (intermedia or major)
  • Hgb H disease
  • Hgb H with non-deletional mutations (e.g., Hgb H Constant Spring)
  • E-B-thalassemia
  • Homozygous alpha thalassemia
  • Other thalassemic conditions not explicitly excluded
  • Thalassemia intermedia due to heterozygous B mutation with an alpha excess
  • Participants can be of any race, ethnicity, and either gender.

Exclusion criteria

  • Thalassemia trait (i.e., single recessive B gene mutation, 2 gene alpha mutation) and thalassemia Hgb S, C, or D compound heterozygotes
  • Unwillingness or inability to complete the Brief Pain Inventory (BPI) on a quarterly basis
  • Has had a successful bone marrow transplant

Treatment and study plan

Primary outcomes

  1. Prevalence of Pain

    Time frame: Measured at Month 9

Secondary outcomes

  1. Common Sites of Pain

    Time frame: Measured at Month 9

  2. Pain Occurrence by Age

    Time frame: Measured at Month 9

  3. Impact of Pain on Functioning and Well-being

    Time frame: Measured at Month 9

Sponsors and collaborators

Lead sponsor

Carelon Research

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Acronym: Pain

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 31, 2009
Registry last updated
Jun 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.